Bextra Meta-Analyses Could Be Taken Up At February COX-2 Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug safety committee member Curt Furberg's meta-analysis suggests increased risk of cardiovascular events for patients with osteoarthritis and rheumatoid arthritis taking Bextra versus placebo while Pfizer points to a meta-analysis of 8,000 patients that did not show an effect. Furberg disinvited by FDA to participate in committee meeting following public comments.
You may also be interested in...
COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.
COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.
FDA COX-2 Review Will Include Input From Furberg, Full Rx Safety Advisory Cmte.
After initially being asked not to appear at the meeting, Wake Forest's Furberg is formally re-invited to participate at the Feb 16-18 advisory committee meeting. FDA first invited only two members of the drug safety committee but has expanded its invitation to the full committee.